Wang X, Wang S, Liu ZH, Qi WQ, Zhang Q, Zhang YG, Sun DR, Xu Y, Wang HG, Li ZX, Cong XL, Zhao P, Zhou CY, Wang JB. Regulatory polymorphism of CXCL10 rs1439490 in seronegative occult hepatitis C virus infection. World J Gastroenterol 2018; 24(20): 2191-2202 [PMID: 29853737 DOI: 10.3748/wjg.v24.i20.2191]
Corresponding Author of This Article
Jiang-Bin Wang, MD, PhD, Professor, Department of Digestive, China-Japan Union Hospital Affiliated to Jilin University, No.126 Xiantai Street, Changchun 130033, Jilin Province, China. zrlwangjb@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 28, 2018; 24(20): 2191-2202 Published online May 28, 2018. doi: 10.3748/wjg.v24.i20.2191
Table 1 Algorithm for evaluation of histological activity
Piecemeal necrosis
+
Lobular necrosis
=
Histological activity score
0 (none)
0 (none or mild)
0 (none)
0
1 (moderate)
1 (mild)
0
2 (severe)
2 (moderate)
1 (mild)
0, 1
1
1
2
2
2 (moderate)
0, 1
2
2
2
3 (severe)
3 (severe)
0, 1, 2
3
Table 2 Fibrosis scoring
Description
Score
No fibrosis
0
Stellate enlargement of portal tract but without septa formation
1
Enlargement of portal tract with rare septa formation
2
Numerous septa without cirrhosis
3
Cirrhosis
4
Table 3 Clinical characteristics of patients enrolled in this study n (%)
Seronegative OCI patients (n = 103)
Seropositive CHC patients (n = 155)
P value
Gender
0.664
Male
58 (56.3)
83 (53.5)
Female
45 (43.7)
72 (46.5)
Age (yr)
52.16 ± 7.64
42.70 ± 9.15
< 0.001
ALT (IU/L)
61.13 ± 23.54
93.17 ± 55.39
< 0.001
GGT
56.31 ± 16.63
52.86 ± 15.69
0.093
BMI
23.73 ± 2.38
24.12 ± 2.36
0.192
HOMA-IR
2.39 ± 0.15
2.42 ± 0.18
0.219
Transfusion/surgery/tattoo history
8 (7.8)
26 (16.8)
0.027
Family history of HCV infection
29 (28.2)
19 (12.3)
< 0.001
Intrahepatic HCV RNA (log10 IU/mL)
3.19 ± 1.05
5.48 ± 1.49
< 0.001
HCV genotype
0.89
Genotype 1
66 (64.1)
98 (63.2)
Non-genotype 1
37 (35.9)
57 (36.8)
Fibrosis (Fibroscan)
0.317
F0-1
65 (63.1)
104 (67.1)
F2-4
38 (36.9)
51 (32.9)
METAVIR activity score
1.14 ± 0.34
1.69 ± 0.68
< 0.001
METAVIR fibrosis score
1.82 ± 0.98
1.87 ± 1.07
0.673
Table 4 IL-28B single nucleotide polymorphism rs12979860 and CXCL10 single nucleotide polymorphism G-201A, C-1513T in occult hepatitis C virus infection and chronic hepatitis C virus infection patients n (%)
Seronegative OCI patients (n=103)
Seropositive CHC patients (n=155)
P value
IL-28BSNP rs12979860
C/C
97 (94.2%)
128 (82.6%)
0.009
Non-C/C
6 (5.8%)
27 (17.4%)
CXCL10 SNP rs1439490 (G-201A)
G/G
93 (90.4%)
116 (74.8%)
0.003
G/A
9 (8.7%)
35 (22.6%)
A/A
1 (0.9%)
4 (2.6%)
CXCL10 SNP rs1440802 (C-1513T)
C/C
26 (25.2%)
40 (25.8%)
0.733
C/T
54 (52.4%)
78 (50.3%)
T/T
23 (22.4%)
37 (23.9%)
Table 5 CXCL10 single nucleotide polymorphism G-201A in occult hepatitis C virus infection and chronic hepatitis C virus infection patients with IL-28B rs12979860 C/C n (%)
Seronegative OCI patients (n = 97)
Seropositive CHC patients (n = 128)
P value
OR (95%CI)
G/G
87 (89.7)
95 (74.2)
0.005
0.331 (0.154-0.711)
Non-G/G (G/A + A/A)
10 (10.3)
33(25.8)
Table 6 Intrahepatic hepatitis C virus RNA, CXCL10 mRNA, and METAVIR scores of 8 seronegative occult hepatitis C virus infection patients who underwent a second liver biopsy
Patient ID
CXCL10G-201A SNP
Intrahepatic HCV RNA (log10 IU/mL)
Relative liver CXCL10 mRNA
METAVIRnecroinflammation score
METAVIRfibrosis scores
Before
After
Before
After
Before
After
Before
After
1
G/G
2.17
(-)
1.20
0.80
1
0
0
0
2
G/G
3.57
(-)
0.95
0.90
1
0
1
1
3
G/G
2.72
(-)
0.74
0.63
1
1
1
1
4
G/G
5.08
(-)
1.31
0.94
1
0
1
0
5
G/G
2.83
(-)
1.42
0.64
1
0
0
0
6
G/G
1.97
(-)
1.06
0.83
2
1
1
1
7
G/G
4.64
(-)
1.03
0.70
2
0
2
1
8
G/G
2.94
(-)
1.26
0.71
1
1
3
1
Table 7 Intrahepatic hepatitis C virus RNA, CXCL10 mRNA, and METAVIR scores of 5 seropositive chronic hepatitis C virus infection patients who underwent a second liver biopsy
Patient ID
CXCL10G-201A SNP
Intrahepatic HCV RNA (log10 IU/mL)
Relative Liver CXCL10 mRNA
METAVIRnecroinflammation score
METAVIRfibrosis scores
Before
After
Before
After
Before
After
Before
After
1
G/G
6.18
(-)
1.93
0.93
1
0
2
1
2
G/G
3.9
(-)
1.80
0.90
2
1
1
1
3
G/A
7.74
1.94
2.78
1.30
2
1
3
2
4
G/A
7.38
(-)
2.39
1.24
2
1
2
2
5
G/G
5.51
1.38
1.31
1.12
1
1
2
1
Table 8 Logistic regression analysis of factors associated with seronegative occult occurrence of hepatitis C virus
Variable
Univariate analysis
Multivariate analysis
OR
95%CI
P value
OR
95%CI
P value
Age
1.15
1.11-1.19
< 0.001
Blood transfusion
0.39
0.17-0.92
0.031
Family history of HCV
3.66
1.85-7.25
< 0.001
Intrahepatic HCV RNA level
0.30
0.23-0.39
< 0.001
IL-28B C/C
0.29
0.12-0.74
0.009
0.28
0.11-0.71
0.008
CXCL10 G-201A G/G
0.32
0.15-0.68
0.003
0.31
0.15-0.66
0.002
Citation: Wang X, Wang S, Liu ZH, Qi WQ, Zhang Q, Zhang YG, Sun DR, Xu Y, Wang HG, Li ZX, Cong XL, Zhao P, Zhou CY, Wang JB. Regulatory polymorphism of CXCL10 rs1439490 in seronegative occult hepatitis C virus infection. World J Gastroenterol 2018; 24(20): 2191-2202